What one share of Lantern Pharma holds
Lantern Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.63 |
|---|---|
| Cash and investments | $0.58 |
| Book value | −$0.25 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$1.23 | — | — | — | $0.48 |
| 2020 | — | −$1.37 | — | — | — | $3.17 |
| 2021 | — | −$1.13 | $0.00 | −$0.97 | — | $6.45 |
| 2022 | — | −$1.31 | $0.00 | −$1.18 | — | $5.16 |
| 2023 | — | −$1.47 | $0.00 | −$1.32 | — | $3.82 |
| 2024 | — | −$1.93 | $0.00 | −$1.66 | — | $1.96 |
| 2025 | — | −$1.57 | $0.00 | −$1.44 | — | $0.58 |
Common questions about Lantern Pharma
How much does one share of Lantern Pharma earn?
Over the last 12 months, Lantern Pharma lost $1.63 for each share.
Does Lantern Pharma pay a dividend?
Lantern Pharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Lantern Pharma’s book value per share?
Lantern Pharma’s book value is negative (−$0.25 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Lantern Pharma have?
Each share of Lantern Pharma has $0.58 of cash and investments, as of June 30, 2026.
Has Lantern Pharma bought back shares?
Lantern Pharma’s share count rose about 451% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.